Expert Highlights Early Efficacy Seen With Mosunetuzumab in Follicular Lymphoma and DLBCL
February 28th 2019In an interview with <em>Targeted Oncology </em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.
Fowler Highlights Trials Accruing at MD Anderson for Relapsed/Refractory Follicular Lymphoma
February 28th 2019In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.
Expert Highlights Ongoing Research Efforts to Advance Treatment Paradigm in Follicular Lymphoma
February 27th 2019In an interview with <em>Targeted Oncology, </em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.
Encouraging PFS Data Seen With Maintenance Ixazomib in Multiple Myeloma
February 21st 2019In findings from a final PFS analysis of the phase III TOURMALINE-MM3 trial presented during the 2019 Transplantation and Cellular Therapy Meetings, 2-year maintenance therapy with the oral proteasome inhibitor ixazomib following autologous stem cell transplantation improved progression-free survival in patients with multiple myeloma.
Expert Underscores Importance of Gaining Better Understanding of Mutations in Myelofibrosis
February 8th 2019Angela G. Fleischman, MD, PhD, discusses a clinical trial at her institution investigating the JAK1 inhibitor itacitinib in patients with MF. She also highlights other recent advancements for patients with MF, as well as advancements in other MPNs such as ET and PV.
Subgroup Analysis Shows Benefit With Ibrutinib Plus R-CHOP in Younger Patients With DLBCL
January 22nd 2019Anas Younes, MD, discusses findings from a subset analysis from the PHOENIX trial in patients with DLBCL. He also highlights another trial investigating R-CHOP plus a PD-L1 inhibitor in this patient population.
Expert Discusses Promising Findings With Imetelstat in Advanced Myelofibrosis
January 17th 2019John O. Mascarenhas, MD, discusses with <em>Targeted Oncology </em>the recent advancements being made in the treatment of patients with advanced myelofibrosis and highlights some of the unmet needs that still exist within this space.
Expert Highlights Responses Seen With Ibrutinib Plus CAR T-Cell Therapy Combination in CLL
January 10th 2019Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.
Cancer Death Rates on the Decline, 2019 Cancer Stats Report Shows
January 10th 2019Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on cancer rates.
Expert Discusses Research Using Ceramide Liposome Particles With Immunotherapy to Treat HCC
December 22nd 2018Kevin Staveley-O’Carroll, MD, PhD, discusses how the field of HCC has advanced over the last few years and how a mouse model at the University of Missouri is being used to further investigate immunotherapy treatment options.<br />
Voorhees Highlights Encouraging Findings With Daratumumab Plus RVd in Myeloma
December 14th 2018In an interview with <em>Targeted Oncology </em>during the 2018 ASH Annual Meeting<em>, </em>Peter Voorhees, MD, discussed the safety and efficacy findings from the safety run-in cohort and the next steps for the Griffin study.
Hematology Experts Weigh In on Top Abstracts at 2018 ASH Annual Meeting
December 6th 2018Although there were a variety of encouraging data presented at the 2018 ASH Annual Meeting, CLL and multiple myeloma undoubtedly ruled the day, according to poll results. As these topics heated up on Twitter, a few experts took a moment to discuss their thoughts on some of the top abstracts that were presented.